IL211841A0 - Disubstituted phthalazine hedgehog pathway antagonists - Google Patents

Disubstituted phthalazine hedgehog pathway antagonists

Info

Publication number
IL211841A0
IL211841A0 IL211841A IL21184111A IL211841A0 IL 211841 A0 IL211841 A0 IL 211841A0 IL 211841 A IL211841 A IL 211841A IL 21184111 A IL21184111 A IL 21184111A IL 211841 A0 IL211841 A0 IL 211841A0
Authority
IL
Israel
Prior art keywords
hedgehog pathway
pathway antagonists
disubstituted phthalazine
phthalazine hedgehog
disubstituted
Prior art date
Application number
IL211841A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41566219&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL211841(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL211841A0 publication Critical patent/IL211841A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL211841A 2008-11-03 2011-03-21 Disubstituted phthalazine hedgehog pathway antagonists IL211841A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11070308P 2008-11-03 2008-11-03
PCT/US2009/061573 WO2010062507A1 (en) 2008-11-03 2009-10-22 Disubstituted phthalazine hedgehog pathway antagonists

Publications (1)

Publication Number Publication Date
IL211841A0 true IL211841A0 (en) 2011-06-30

Family

ID=41566219

Family Applications (1)

Application Number Title Priority Date Filing Date
IL211841A IL211841A0 (en) 2008-11-03 2011-03-21 Disubstituted phthalazine hedgehog pathway antagonists

Country Status (29)

Country Link
US (1) US8404687B2 (index.php)
EP (1) EP2364185B1 (index.php)
JP (1) JP2012507535A (index.php)
KR (1) KR101335746B1 (index.php)
CN (1) CN102202737B (index.php)
AU (1) AU2009320251C1 (index.php)
BR (1) BRPI0921437A2 (index.php)
CA (1) CA2742539C (index.php)
CL (1) CL2011000979A1 (index.php)
CO (1) CO6382123A2 (index.php)
CR (1) CR20110202A (index.php)
CY (1) CY1114023T1 (index.php)
DK (1) DK2364185T3 (index.php)
EA (1) EA018931B1 (index.php)
EC (1) ECSP11011021A (index.php)
ES (1) ES2418479T3 (index.php)
HR (1) HRP20130527T1 (index.php)
IL (1) IL211841A0 (index.php)
MA (1) MA32726B1 (index.php)
MX (1) MX2011004683A (index.php)
NZ (1) NZ591945A (index.php)
PE (1) PE20110433A1 (index.php)
PL (1) PL2364185T3 (index.php)
PT (1) PT2364185E (index.php)
SI (1) SI2364185T1 (index.php)
TN (1) TN2011000166A1 (index.php)
UA (1) UA102115C2 (index.php)
WO (1) WO2010062507A1 (index.php)
ZA (1) ZA201102448B (index.php)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009009873A (es) * 2007-03-15 2009-09-24 Novartis Ag Compuestos organicos y sus usos.
AU2009241561B2 (en) 2008-04-29 2013-05-16 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
BRPI0921782A2 (pt) 2008-11-17 2019-09-24 Lilly Co Eli antagonistas da via hedgehog de piridazina tetrassubstituída
MX2011005176A (es) 2008-11-17 2011-05-30 Lilly Co Eli Antagonistas de la trayectoria hedgehog de piridazinas tetrasustituidas.
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
WO2015073691A1 (en) 2013-11-14 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of bmp signaling
CN105985320B (zh) * 2015-02-11 2018-10-26 复旦大学 苄基酞嗪化合物及其制备方法和用途
CN105985319B (zh) * 2015-02-11 2019-02-26 复旦大学 芳基酞嗪化合物及其制备方法和用途
CN105985321B (zh) * 2015-02-11 2018-10-26 复旦大学 吡唑酞嗪化合物及其制备方法和用途
AU2021360767A1 (en) 2020-10-13 2023-04-27 Endeavor Biomedicines, Inc. Methods of treating fibrosis
PE20251293A1 (es) * 2022-09-23 2025-05-14 Merck Sharp And Dohme Llc Derivados de ftalazina utiles como inhibidores de la proteina receptora 3 similar a nod
WO2025188802A1 (en) 2024-03-05 2025-09-12 Endeavor Biomedicines, Inc. Methods of improving lung function

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
WO1998014431A1 (en) * 1996-10-01 1998-04-09 Kyowa Hakko Kogyo Co., Ltd. Nitrogenous heterocyclic compounds
CA2237273C (en) * 1996-01-15 2009-01-13 Janssen Pharmaceutica N.V. Angiogenesis inhibiting pyridazinamines
US6432970B2 (en) * 1998-04-09 2002-08-13 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
JP5067986B2 (ja) 1998-04-09 2012-11-07 ジョンズ ホプキンズ ユニヴァーシティー スクール オブ メディシン ヘッジホッグシグナリング経路の阻害剤としてのステロイドアルカロイド誘導体の使用
ATE283700T1 (de) 1999-06-08 2004-12-15 Lorantis Ltd Therapeutische verwendung eines inhibitors des hedgehog signalübertragungsweges
EP1496905B1 (en) 2002-04-22 2008-08-13 Johns Hopkins University School of Medicine Modulators of hedgehog signaling pathways, compositions and uses related thereto
WO2004020599A2 (en) 2002-08-29 2004-03-11 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
US8067608B2 (en) 2003-09-29 2011-11-29 The Johns Hopkins University Hedgehog pathway antagonists
WO2005080378A1 (ja) 2004-02-24 2005-09-01 Mitsubishi Pharma Corporation 縮合ピリダジン誘導体
WO2006004589A2 (en) 2004-05-08 2006-01-12 Neurogen Corporation 3-aryl-5,6-disubstituted pyridazines
UA96565C2 (ru) * 2004-09-02 2011-11-25 Дженентек, Инк. Пиридильные ингибиторы хеджхоговской передачи сигнала
EP1900731A1 (de) 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
MX2009009873A (es) 2007-03-15 2009-09-24 Novartis Ag Compuestos organicos y sus usos.
ES2505091T3 (es) * 2007-06-25 2014-10-09 Amgen Inc. Compuestos, composiciones y métodos de uso de ftalazina
WO2009035568A1 (en) 2007-09-07 2009-03-19 Amgen Inc. Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling
AU2009241561B2 (en) 2008-04-29 2013-05-16 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
BRPI0921782A2 (pt) 2008-11-17 2019-09-24 Lilly Co Eli antagonistas da via hedgehog de piridazina tetrassubstituída
MX2011005176A (es) 2008-11-17 2011-05-30 Lilly Co Eli Antagonistas de la trayectoria hedgehog de piridazinas tetrasustituidas.
AR077014A1 (es) * 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer

Also Published As

Publication number Publication date
PL2364185T3 (pl) 2013-10-31
KR101335746B1 (ko) 2013-12-12
AU2009320251C1 (en) 2013-08-15
CN102202737A (zh) 2011-09-28
AU2009320251B2 (en) 2013-01-24
HK1159010A1 (en) 2012-07-27
PT2364185E (pt) 2013-07-24
ZA201102448B (en) 2012-09-26
ES2418479T3 (es) 2013-08-14
ECSP11011021A (es) 2011-06-30
US20110190304A1 (en) 2011-08-04
EP2364185A1 (en) 2011-09-14
MX2011004683A (es) 2011-06-20
SI2364185T1 (sl) 2013-07-31
CR20110202A (es) 2011-06-09
EP2364185B1 (en) 2013-05-22
NZ591945A (en) 2012-10-26
EA201170640A1 (ru) 2011-12-30
MA32726B1 (fr) 2011-10-02
HRP20130527T1 (en) 2013-07-31
CA2742539A1 (en) 2010-06-03
CN102202737B (zh) 2014-03-26
CA2742539C (en) 2014-05-06
JP2012507535A (ja) 2012-03-29
DK2364185T3 (da) 2013-06-03
CO6382123A2 (es) 2012-02-15
CY1114023T1 (el) 2016-07-27
PE20110433A1 (es) 2011-07-09
KR20110066212A (ko) 2011-06-16
AU2009320251A1 (en) 2010-06-03
WO2010062507A1 (en) 2010-06-03
EA018931B1 (ru) 2013-11-29
US8404687B2 (en) 2013-03-26
UA102115C2 (ru) 2013-06-10
BRPI0921437A2 (pt) 2018-10-30
CL2011000979A1 (es) 2011-10-07
TN2011000166A1 (en) 2012-12-17

Similar Documents

Publication Publication Date Title
IL208211A0 (en) Disubstituted phthalazine hedgehog pathway antagonists
ZA201108587B (en) Disubstituted phthalazine hedgehog pathway antagonists
IL211841A0 (en) Disubstituted phthalazine hedgehog pathway antagonists
IL237392A0 (en) Pharmaceutical combination
IL229059A (en) 9pcsk antagonists
IL207378A0 (en) Pharmaceutical solid state forms
DK2301489T3 (en) Tredimensionelt ortopædisk udstyr til rygsøjlen
GB201106730D0 (en) Analyzing event
AU322206S (en) Monitor
HU0800591D0 (en) Stable pharmaceutical combination
IL208953A0 (en) Pharmaceutical combination
HU0800414D0 (en) Pharmaceutical combination
HK1153467A (en) Disubstituted phthalazine hedgehog pathway antagonists
GB0818712D0 (en) Therapeutic substances
GB0804377D0 (en) Therapeutic substances
GB0812816D0 (en) Therapeutic substances
GB0810952D0 (en) Therapeutic substances
GB0802576D0 (en) Dosage form
AU2008298V (en) Proquest D3 Dianella caerulea
GB0807453D0 (en) General problem solver
HU0800039V0 (en) Construction set
GB0819442D0 (en) Monitor
GB0805729D0 (en) K9 easybath
GB0704123D0 (en) Dosage form